Search

Yunfu Hu Phones & Addresses

  • 107 Manora Ln, Chapel Hill, NC 27516 (919) 928-8770 (919) 969-0926
  • Laurel, MD
  • s
  • 6196 Devon Dr, Columbia, MD 21044
  • Sparks, MD
  • Philadelphia, PA
  • 8649 Vintage Earth Path, Laurel, MD 20723

Publications

Us Patents

Biomarkers For Fatty Liver Disease And Methods Using The Same

View page
US Patent:
20100279956, Nov 4, 2010
Filed:
Apr 30, 2010
Appl. No.:
12/771729
Inventors:
Bruce J. MC CREEDY, JR. - Raleigh NC, US
Alvin Berger - Raleigh NC, US
YunFu Hu - Chapel Hill NC, US
Satish C. Kalhan - Pepper Pike OH, US
International Classification:
A61K 31/7004
C12Q 1/00
G01N 33/53
C12Q 1/02
G01N 33/00
G01N 30/02
A61K 31/66
A61K 31/60
A61K 31/56
A61K 31/415
A61K 31/195
US Classification:
514 23, 435 4, 435 71, 435 792, 435 29, 436 86, 436 94, 436104, 436128, 436161, 514114, 514159, 514179, 514400, 514561
Abstract:
The present invention provides various biomarkers of fatty liver disease, including steatosis and steatohepatitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of fatty liver disease, methods of determining predisposition to fatty liver disease, methods of monitoring progression/regression of fatty liver disease, methods of assessing efficacy of compositions for treating fatty liver disease, methods of screening compositions for activity in modulating biomarkers of fatty liver disease, methods of treating fatty liver disease, as well as other methods based on biomarkers of fatty liver disease.

Biomarkers For Fatty Liver Disease And Methods Using The Same

View page
US Patent:
20150377910, Dec 31, 2015
Filed:
Sep 2, 2015
Appl. No.:
14/843356
Inventors:
- Durham NC, US
- Cleveland OH, US
YunFu HU - Chapel Hill NC, US
Satish C. KALHAN - Pepper Pike OH, US
International Classification:
G01N 33/68
H01J 49/00
Abstract:
The present invention provides various biomarkers of fatty liver disease, including steatosis and steatohepatitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of fatty liver disease, methods of determining predisposition to fatty liver disease, methods of monitoring progression/regression of fatty liver disease, methods of assessing efficacy of compositions for treating fatty liver disease, methods of screening compositions for activity in modulating biomarkers of fatty liver disease, methods of treating fatty liver disease, as well as other methods based on biomarkers of fatty liver disease.
Yunfu F Hu from Chapel Hill, NC Get Report